Aims & Scope
The Clinical Lung Cancer is a peer-reviewed, open-access journal published by Directive Publications and devoted to the diagnosis, treatment, and prevention of thoracic malignancies. As a clinical lung cancer journal, it publishes original research, reviews, clinical trials, and case reports spanning non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), lung adenocarcinoma, and rare pulmonary tumors, bridging laboratory science and bedside oncology practice.
The journal welcomes work across the full disease continuum: low-dose CT screening and pulmonary nodule management; molecular oncology and biomarkers including EGFR, ALK, ROS1, KRAS and FGFR alterations; targeted therapy and immune checkpoint inhibition; surgical, radiation, and systemic treatment; and survivorship. We particularly encourage studies applying artificial intelligence, deep learning, and radiomics to nodule classification, malignancy prediction, and theranostics.
Intended for thoracic oncologists, pulmonologists, radiologists, pathologists, surgeons, and translational researchers, the journal advances evidence that improves clinical decision-making and patient outcomes worldwide.
Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) license with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, in line with COPE ethical principles.
Subject Coverage
The Clinical Lung Cancer welcomes original research, reviews, and case reports across the following core areas:
Research Topics
Core subject areas published in The Clinical Lung Cancer — explore related research across our journals.
Articles
Predictive capacity for malignancy of the scales for evaluation of pulmonary nodules in oncological patients at the national institute of cancerology between 2012–2022
Lung Cancer Risk factors - A Review Article
Advances and Prospect of Artificial Intelligence in Theranostics of Lung Cancer
Frequently Asked Questions
What topics does The Clinical Lung Cancer journal cover?
The Clinical Lung Cancer covers the full spectrum of thoracic oncology: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), lung adenocarcinoma and rare pulmonary tumors, low-dose CT screening and pulmonary nodule management, molecular biomarkers such as EGFR, ALK, ROS1, KRAS and FGFR, targeted therapy and immunotherapy, radiation and surgical oncology, and AI/deep-learning applications in diagnosis and theranostics.
Who should read and publish in The Clinical Lung Cancer?
The journal serves thoracic and medical oncologists, pulmonologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, and translational and clinical researchers. It is ideal for authors reporting lung cancer clinical trials, screening and nodule-management studies, molecular and biomarker research, immunotherapy outcomes, and AI-driven imaging work who want open-access reach to a global oncology audience.
What article types does The Clinical Lung Cancer accept?
We accept original research articles, randomized and observational clinical studies, systematic reviews and meta-analyses, narrative and expert reviews, case reports (such as rare lung tumors or unusual molecular findings), brief communications, and editorials addressing clinical, translational, and methodological aspects of lung cancer.
How do I submit a manuscript to The Clinical Lung Cancer?
Authors submit through the journal's submission page on Directive Publications. Prepare your manuscript per our author guidelines, include structured abstract, declarations, and reporting-checklist where applicable (CONSORT, PRISMA, CARE), and our editorial team will route it to double-blind peer review by lung cancer specialists.
Is The Clinical Lung Cancer open access, and how is peer review handled?
Yes. The Clinical Lung Cancer is fully open access: accepted articles are published under a Creative Commons CC-BY 4.0 license with authors retaining copyright, and each receives a permanent Crossref DOI. Every submission undergoes double-blind peer review conducted by independent experts in thoracic oncology, following COPE ethical principles.
Is there an article processing charge, and are waivers available?
An article processing charge applies only on acceptance to sustain open-access publishing, editorial handling, and DOI registration. Discounts and full waivers are available for authors with limited funding; contact the editorial office before or during submission to request consideration. There are no charges for rejected manuscripts.
Where is The Clinical Lung Cancer indexed and discoverable?
Articles are assigned Crossref DOIs and are discoverable through OpenAlex and Google Scholar, with full metadata exposed via an OAI-PMH endpoint for harvesting. As a new open-access journal, The Clinical Lung Cancer is actively working toward broader indexing, including preparing for its DOAJ application and pursuing eligibility for additional biomedical databases.
Does The Clinical Lung Cancer publish AI and lung cancer screening studies?
Yes. The journal actively welcomes research on low-dose CT screening, pulmonary nodule and ground-glass/subsolid nodule management, radiomics, and artificial intelligence and deep learning for malignancy prediction, nodule classification, and theranostics, alongside conventional clinical and translational lung cancer studies.